NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EW stock has increased by 5.2% and is now trading at $69.19. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences will be holding an earnings conference call on Thursday, July 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings data on Thursday, April, 23rd. The medical research company reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.07. The medical research company had revenue of $1.13 billion for the quarter, compared to analysts' expectations of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The business's revenue was up 13.7% on a year-over-year basis. During the same period last year, the firm earned $0.44 EPS. View Edwards Lifesciences' earnings history.

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, April, 23rd. The company provided EPS guidance of $4.75-5.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.46. The company issued revenue guidance of $4.00-4.50 billion, compared to the consensus revenue estimate of $4.08 billion.

23 equities research analysts have issued 1-year target prices for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $100.00. On average, they expect Edwards Lifesciences' stock price to reach $82.77 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

Media coverage about EW stock has trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Edwards Lifesciences.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Adobe (ADBE), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&R Capital Management Inc. (0.00%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

EW stock was acquired by a variety of institutional investors in the last quarter, including M&R Capital Management Inc.. View insider buying and selling activity for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $69.19.

Edwards Lifesciences has a market capitalization of $42.87 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]